Genetics Generation Advancement Corp. Logo

Genetics Generation Advancement Corp.

4160.TWO

()
Stock Price

80 TWD

5.74% ROA

9.25% ROE

51.3x PER

Market Cap.

2.394.119.910 TWD

7.41% DER

0.56% Yield

6.8% NPM

Genetics Generation Advancement Corp. Stock Analysis

Genetics Generation Advancement Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Genetics Generation Advancement Corp. Fundamental Stock Analysis
# Analysis Rating

Genetics Generation Advancement Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Genetics Generation Advancement Corp. Technical Stock Analysis
# Analysis Recommendation

Genetics Generation Advancement Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Genetics Generation Advancement Corp. Revenue
Year Revenue Growth
2020 443.130.000
2021 519.511.000 14.7%
2022 547.809.000 5.17%
2023 592.500.000 7.54%
2024 678.412.000 12.66%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Genetics Generation Advancement Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2020 32.089.000
2021 51.001.000 37.08%
2022 52.323.000 2.53%
2023 54.468.000 3.94%
2024 66.160.000 17.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Genetics Generation Advancement Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2020 41.821.000
2021 46.392.000 9.85%
2022 45.778.000 -1.34%
2023 44.786.000 -2.21%
2024 48.580.000 7.81%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Genetics Generation Advancement Corp. EBITDA
Year EBITDA Growth
2020 -10.679.000
2021 20.479.000 152.15%
2022 44.721.000 54.21%
2023 49.927.000 10.43%
2024 106.916.000 53.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Genetics Generation Advancement Corp. Gross Profit
Year Gross Profit Growth
2020 141.289.000
2021 195.494.000 27.73%
2022 226.436.000 13.66%
2023 236.830.000 4.39%
2024 306.920.000 22.84%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Genetics Generation Advancement Corp. Net Profit
Year Net Profit Growth
2020 -15.705.000
2021 7.839.000 300.34%
2022 25.731.000 69.53%
2023 28.565.000 9.92%
2024 72.740.000 60.73%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Genetics Generation Advancement Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2020 -1
2021 0 0%
2022 1 100%
2023 1 0%
2024 3 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Genetics Generation Advancement Corp. Free Cashflow
Year Free Cashflow Growth
2019 0
2020 6.290.000 100%
2021 -3.106.000 302.51%
2022 43.666.000 107.11%
2023 61.742.000 29.28%
2024 -10.638.000 680.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Genetics Generation Advancement Corp. Operating Cashflow
Year Operating Cashflow Growth
2019 0
2020 26.692.000 100%
2021 7.324.000 -264.45%
2022 51.808.000 85.86%
2023 66.857.000 22.51%
2024 6.419.000 -941.55%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Genetics Generation Advancement Corp. Capital Expenditure
Year Capital Expenditure Growth
2019 0
2020 20.402.000 100%
2021 10.430.000 -95.61%
2022 8.142.000 -28.1%
2023 5.115.000 -59.18%
2024 17.057.000 70.01%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Genetics Generation Advancement Corp. Equity
Year Equity Growth
2020 311.932.000
2021 318.696.000 2.12%
2022 347.461.000 8.28%
2023 430.146.000 19.22%
2024 612.097.000 29.73%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Genetics Generation Advancement Corp. Assets
Year Assets Growth
2020 409.135.000
2021 424.757.000 3.68%
2022 455.663.000 6.78%
2023 595.053.000 23.42%
2024 790.403.000 24.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Genetics Generation Advancement Corp. Liabilities
Year Liabilities Growth
2020 97.203.000
2021 106.061.000 8.35%
2022 108.202.000 1.98%
2023 164.907.000 34.39%
2024 178.306.000 7.51%

Genetics Generation Advancement Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
25.7
Net Income per Share
1.75
Price to Earning Ratio
51.3x
Price To Sales Ratio
3.69x
POCF Ratio
36.58
PFCF Ratio
57.43
Price to Book Ratio
3.7
EV to Sales
3.61
EV Over EBITDA
32.65
EV to Operating CashFlow
37.85
EV to FreeCashFlow
56.22
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
2 Bil.
Enterprise Value
2 Bil.
Graham Number
30.87
Graham NetNet
15.99

Income Statement Metrics

Net Income per Share
1.75
Income Quality
1.14
ROE
0.09
Return On Assets
0.06
Return On Capital Employed
0.09
Net Income per EBT
0.81
EBT Per Ebit
0.99
Ebit per Revenue
0.08
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0.07
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.41
Operating Profit Margin
0.08
Pretax Profit Margin
0.08
Net Profit Margin
0.07

Dividends

Dividend Yield
0.01
Dividend Yield %
0.56
Payout Ratio
0
Dividend Per Share
0.51

Operating Metrics

Operating Cashflow per Share
2.45
Free CashFlow per Share
1.65
Capex to Operating CashFlow
0.33
Capex to Revenue
0.03
Capex to Depreciation
1.2
Return on Invested Capital
0.07
Return on Tangible Assets
0.06
Days Sales Outstanding
70.74
Days Payables Outstanding
45.38
Days of Inventory on Hand
34.22
Receivables Turnover
5.16
Payables Turnover
8.04
Inventory Turnover
10.67
Capex per Share
0.8

Balance Sheet

Cash per Share
18,61
Book Value per Share
24,23
Tangible Book Value per Share
23.42
Shareholders Equity per Share
24.22
Interest Debt per Share
1.82
Debt to Equity
0.07
Debt to Assets
0.06
Net Debt to EBITDA
-0.7
Current Ratio
3.67
Tangible Asset Value
1 Bil.
Net Current Asset Value
0 Bil.
Invested Capital
526124000
Working Capital
0 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0 Bil.
Average Payables
0 Bil.
Average Inventory
35256000
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Genetics Generation Advancement Corp. Dividends
Year Dividends Growth
2018 0
2019 1 0%
2020 1 0%
2022 0 0%
2023 0 0%
2024 1 0%

Genetics Generation Advancement Corp. Profile

About Genetics Generation Advancement Corp.

Genetics Generation Advancement Corp. provides genetic testing and informatics services in Taiwan, Asia, Europe, and the Americas. The company offers pre-pregnancy test, pregnancy test, newborn testing, adult health management genetic testing, adult cancer and pharmacogenetic testing, and cooperative institutes. It also provides life sciences, materials sciences, laboratory informatics, enterprise quality management system, MES, electronic delivery services. The company was formerly known as Genesis Genetics Asia Corp. and changed its name to Genetics Generation Advancement Corp. in February 2016. Genetics Generation Advancement Corp. was founded in 2008 and is based in Taipei, Taiwan.

CEO
Yu Chun Liu
Employee
0
Address
No. 28, Xinhu 1st Road
Taipei, 11494

Genetics Generation Advancement Corp. Executives & BODs

Genetics Generation Advancement Corp. Executives & BODs
# Name Age
1 Yu Chun Liu
Chief Financial Officer and Executive Vice President
70
2 Yuchun Xiao
Accounting Supervisor
70
3 John Chang
Chief Technical Officer
70

Genetics Generation Advancement Corp. Competitors